AAAAAA

   
Results: 1-9 |
Results: 9
Clinical pharmacokinetics of capecitabine
Authors: Reigner, B Blesch, K Weidekamm, E
Citation: B. Reigner et al., Clinical pharmacokinetics of capecitabine, CLIN PHARMA, 40(2), 2001, pp. 85-104
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
Authors: Schuller, J Cassidy, J Dumont, E Roos, B Durston, S Banken, L Utoh, M Mori, K Weidekamm, E Reigner, B
Citation: J. Schuller et al., Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients, CANC CHEMOT, 45(4), 2000, pp. 291-297
A phase I and pharmacokinetic study of the combination of capecitabine anddocetaxel in patients with advanced solid tumours
Authors: Pronk, LC Vasey, P Sparreboom, A Reigner, B Planting, AST Gordon, RJ Osterwalder, B Verweij, J Twelves, C
Citation: Lc. Pronk et al., A phase I and pharmacokinetic study of the combination of capecitabine anddocetaxel in patients with advanced solid tumours, BR J CANC, 83(1), 2000, pp. 22-29
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
Authors: Twelves, C Glynne-Jones, R Cassidy, J Schuller, J Goggin, T Roos, B Banken, L Utoh, M Weidekamm, E Reigner, B
Citation: C. Twelves et al., Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites, CLIN CANC R, 5(7), 1999, pp. 1696-1702
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
Authors: Villalona-Calero, MA Weiss, GR Burris, HA Kraynak, M Rodrigues, G Drengler, RL Eckhardt, SG Reigner, B Moczygemba, J Burger, HU Griffin, T Von Hoff, DD Rowinsky, EK
Citation: Ma. Villalona-calero et al., Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies, J CL ONCOL, 17(6), 1999, pp. 1915-1925
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients
Authors: Cassidy, J Twelves, C Cameron, D Steward, W O'Byrne, K Jodrell, D Banken, L Goggin, T Jones, D Roos, B Bush, E Weidekamm, E Reigner, B
Citation: J. Cassidy et al., Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients, CANC CHEMOT, 44(6), 1999, pp. 453-460
Influence of the antacid Maalox on the pharmacokinetics of capecitabine incancer patients
Authors: Reigner, B Clive, S Cassidy, J Jodrell, D Schulz, R Goggin, T Banken, L Roos, B Utoh, M Mulligan, T Weidekamm, E
Citation: B. Reigner et al., Influence of the antacid Maalox on the pharmacokinetics of capecitabine incancer patients, CANC CHEMOT, 43(4), 1999, pp. 309-315
Prediction of hepatic metabolic clearance based on interspecies allometricscaling techniques and in vitro in vivo correlations
Authors: Lave, T Coassolo, P Reigner, B
Citation: T. Lave et al., Prediction of hepatic metabolic clearance based on interspecies allometricscaling techniques and in vitro in vivo correlations, CLIN PHARMA, 36(3), 1999, pp. 211-231
A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of C-14-labelled drug
Authors: Judson, IR Beale, PJ Trigo, JM Aherne, W Crompton, T Jones, D Bush, E Reigner, B
Citation: Ir. Judson et al., A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of C-14-labelled drug, INV NEW DR, 17(1), 1999, pp. 49-56
Risultati: 1-9 |